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Plasma vitamin C concentrations in patients with cystic 
fibrosis: evidence of associations with lung inflammation1-4
Brigitte M  Winklhofer-Rooh, Helmut El temimi er, Martin Friihwirth, Susanna E Schlegel-Haueter, 
GholamaU Khoschsontr, Martin A van’t Hof, and David H  Shmeiiing
ABSTRACT Vitamin C status and possible associations with 
the disease process in cystic fibrosis (CP) patients were investi­
gated. Plasma vitamin C concentrations in patients from two 
different mid-European populations (Swiss, n =  62; Austrian, 
/j — 60) taking no or low-dose vitamin C from multivitamin 
supplements did not differ from each oilier or from control subjects 
(» ~  34). Vitamin C concentrations decreased with age (5,05 
/xmol ■ L 1 • y~ '). When followed up for 12 mo, patients had the 
highest plasma vitamin C concentrations in February and the 
lowest in May and August (P <  0.01); the decrease in vitamin C 
was accompanied by increases in plasma malondialdehyde (P < 
0.001) and tumor necrosis factor a concentrations (P <  0.01). 
During supplementation with vitamin E for 2 mo or /3-carotene for
12 mo vitamin C concentrations did not change. They correlated 
inversely with white blood cell count (r — -0.36, P = 0.008), 
bands (r -  -0.36, P = 0.02), a j-acid glycoprotein (/* — —0.45, 
P =  0.002), interleukin 6 (r =  -0.46, P = 0.0006), and neutrophil 
elastase/a,-proteinase inhibitor complexes (r = -0 .34 , P ~  0.02). 
In patients with vitamin C concentrations <  40 /xmol/L, all in­
dexes of inflammation were relatively high, whereas those with 
concentrations >  80 /¿mol/L (upper quartile of control subjects) 
showed clearly lower values. These results are consistent with the 
hypothesis that by scavenging oxygen free radicals vitamin C 
interacts with an in lì am mat ion-amplifying cycle of activation of 
alveolar macrophages and neutrophils, release of proinflammatory 
cytokines and oxygen free radicals, and inactivation of anti pro­
teases, Am J Clin Nutr 1997;65:1858-66.
KEY WORDS Cystic fibrosis, vitamin C, inflammation, 
free radicals, cytokines, malondialdehyde, neutrophil chistase/ 
a  ¡-proteinase inhibitor complexes, Sii wach man score, tumor 
necrosis factor tv
INTRODUCTION
Cystic fibrosis (CF) lung disease is characterized by chronic, 
neutrophil-do min a ted inflammation (1) and unopposed neutro­
phil elastasc activity that contributes to progressive, irrevers­
ible tissue destruction (2). Activated neutrophils and alveolar 
macrophages are a major source of endogenous reactive oxy­
gen species (ROS), which have been implicated in lung inflam­
mation (3). A variety of stimuli such as bacteria, immune 
complexes, leukolrienes, and tumor necrosis factor a  (TNF-a?)
corresponding editorial on page 1891.
enhance the respiratory burst of neutrophils and their degran­
ulation, and consequently, the generation of superoxide and 
hydrogen peroxide (3), ROS mediate signal transduction, in­
cluding the activation of the transcription factor nuclear fac­
tor-* B (NF-kB), which is critical for the inducible expression 
of genes involved in inflammatory [interleukin I (IL-1), ÍL-6, 
and TN F-a] and acute phase responses (4). TNF-o: itself stim­
ulates neutrophils (5) and activates NF-kB (6). In vitro exper­
iments showed that neutrophil elastase stimulates the secretion 
of IL-6 by a CF airway epithelial cell line (7). ROS have been 
shown to impair alveolar- macrophage function and disturb 
membrane integrity (8). Together, all of the above constitute a 
vicious cycle that cannot be interrupted efficiently by the 
therapeutic options currently available.
Vitamin C, a potent water-soluble antioxidant (9-11) present 
at high concentrations in epithelial lining fluid (ELF) (12), is 
considered to play a major role in the extracellular defense 
system of the lung (13). It is accumulated by alveolar macro­
phages and leukocytes (14, 15), the concentration gradient 
between leukocytes and plasma being up to 50-fold (15, 16). 
Because intracellular ascorbic acid is found almost exclusively 
in the cytosol, it has been proposed to have a protective effect 
by reducing ROS that enter the cytosol from the phagolyso­
some (15). On the other hand, ascorbic acid may be secreted 
into the extracellular microenvironment to protect the cell 
membrane against oxidation and thus preserve cellular integrity 
and chemotactic function (15). Ascorbic acid is a potent scav-
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enger o í superoxide radical, hydroxyl radical, and the my­
eloperoxidase-derived oxidant hypochlorous acid (10), all of 
which are released by activated neutrophils into the extracel­
lular environment. Here, ascorbic acid could prevent the oxi­
dative inactivation of a  ¡-proteinase inhibitor (a  ¡-PI) (17). 
Upon phagocytosis, the ascorbic acid content of neutrophils 
decreases (18).
Vitamin C concentrations in plasma are low in critically ill 
patients admitted to the intensive care unit (19), in patients with 
rheumatoid arthritis (18, 20) and bronchial asthma (21), and in 
smokers (22); each is a condition that involves the activation of 
white blood cells (WBCs) and ROS generation.
In contrast with the statuses of vitamin E and other fat- 
soluble vitamins that are substantially impaired in CF patients 
as a result of fat malabsorption, little attention has been paid to 
vitamin C. Data available so far show plasma ascorbic acid 
concentrations in CF patients from England not taking supple­
ments to he either higher than (33.7-850.5 /utmol/L; median 
94,6 jumoI/L) (23) or similar to (23.5-94.2 /¿mol/L; median 
60.1 /¿mo.l/L) those of healthy subjects (24), and in patients 
from North America, total vitamin C (sum of ascorbic and 
dehydroascorbic acids) concentrations were below normal in 
25% (25). Elevated plasma ascorbic acid concentrations in CF 
patients were considered to impair the total radical-trapping 
potential (23), suggesting that vitamin C supplements might 
even be harmful. However, as part of routine therapeutic man­
agement, CF patients frequently take multivitamin preparations 
with low-dose vitamin C. Multivitamin preparations were rec­
ommended by the North American CF Consensus Committee 
in 1992 (26), but recommendations for the vitamin C content of 
these supplements were not given,
We hypothesized that by efficiently scavenging RDS in the 
lung of CF patients, ascorbic acid could interact with an in­
flammation-amplifying cycle of activation of alveolar macro­
phages and neutrophils, release of ROS and proinflammatory 
cytokines, and inactivation of the major antiprotease «j-PÏ. The 
purpose of this observational study was to gain I uri her insight
into the vitamin C status of CF patients and its possible 
associations with the disease process by I) evaluating CF 
patients from two different mid-European populations (Swiss 
and Austrian), because plasma vitamin C concentrations are 
likely to reflect, at least in part, the dietary intake of fruit and 
vegetables rich in vitamin C, which is known to vary among 
populations; and 2) analysing changes over time in plasma 
vitamin C concentrations both in the absence and presence of 
changes in supplementation with other anti oxidants to detect 
possible seasonal influences and interactions between antioxi­
dants, respectively. To answer the question of whether low 
plasma vitamin C concentrations are associated with increased 
lipid peroxidation, plasma malondialdehyde (MDA) concentra­
tions were measured. To investigate possible interactions be­
tween vitamin C status and lung inflammation, relations be­
tween plasma vitamin C concentrations and cytokines (TNlwv 
and IL-6), an acute phase reactant (tv,-acid glycoprotein, a r  
AGP), and other indexes of inflammation | WBCs, bands, and 
neutrophil chistase (NE)/<vr Pi complexes| were studied.
SUBJECTS AND METHODS 
Patients
A total of 122 patients (64 males and 58 females) with a a 
median age of 9.9 y (0.4-37,9 y) and Shwachinan scores (27) 
of 81 ± 17 were investigated. They comprised two cohorts of 
CF patients. Group A included 58 patients from Switzerland 
and 4 patients from Germany; this group is further referred to 
as the Swiss group (n =  62). Group B comprised 60 patients 
from Austria. Demographic data for the two patient groups are 
shown in Table I. Disease severity was assessed by using the 
Shwachinan score (5-25 points are given for each of four 
categories: general activity, physical findings, nutritional sta­
tus, and chest X-ray findings, with a perfect score being 100 
points). Sh wach man scores (to obtain normality the square root, 
of the mirror scale, JÍX) ~  .Shvvachman score, had. to be used)
TABLKt
Comparison of Swiss and Austrian cystic fibrosis (CF) patients taking t) 1 >  mg vitamin C and CF patients and healthy conimi subjects inking no 
supplements7
*****
iV ilro w m rn  rn Tntif? n— f* i
CF paiienis
uiuvu* -WML t. - l.i -í $¿±, »  .fatUbU. ü£ N**
v iv a io
Age (y)
Shwuchman score 
Plasma variables 
Vitamin C í/xmol/L) 
«»Tocopherol (/xmo)/L) 
ß-Carolene (¿xmol/U 
Malondialdehyde (jwnol/U
1 otul .Swiss"'7 Austrian'' Conimi siihjiMs
(/Î
• » y  i
pT)1 4 * * *  f
. : > k  ~-i * p V / i  > •  « X  K V  * -'A* in 62)' A ' . i A J . i ,  i  * i ' , i  i .  • .  i  » . . .  :  *• t A  » im  V ' * "  * - a ¿ j  i  . : r  j in 60)íiÁiT!'.Ü {ty - AiV *>L u  • i'i < I,*: +   ^ ' i '*•,/*■ •  ■ -<■ •.a* • I'á~YA <4*ái l^n; Ui .VI (ì<*:a.'.'ì.4 «i s - «  n ;, a  ï <•'< -  ..............  J‘S, r. '-Z
12.1 * 8.3 1 13) H.l I 12.2 1  K.‘> 71A 6.8
80.6 17.2 79.8 ± 153) 8 l.(i ' IK.5 NA
63.6 ' 18.X 63.3 18.3 (»4.0 1 I1) .5 6<).5 16.6
263) i o i• • 7 fc M 30.1 1 I.ÍV 23.Í» ' 7.7 28.(1 5.6
0.35 0.60" 0,56 0.80™ 0. 1.1 ! (I.Ui 03)2 ‘ 0.*I7
0.69 ■■ 0.26 0.72 0.31 0.M» •!: 0.21 0.72 ' U.28
n  in  !■ n —  r ......................................................... »
; .v ± SIX NA, not applicable.
“ Includes lour patients from Germany.
* All supplemented with vitamin E; 21 also supplemented with ß-caroiene. 
'All supplemented with vitamin E.
s Log,,, value significantly different from Austrian group, P * 0.00(11 (/ test). 
{> l.ogm value significantly different front control subjects, P < 0.0(H)I it test),
7 Logm value significantly different from Austrian group, P < 0.0001 it test). 
H In patients taking ß-carntene supplements (n ;
/J-caroiene.
21 ) concentration was L2() : 0.86 /imol/L compared wilh 0,14 ,4: 0.14 /.unol/L in ihose not taking
1860 WINKLHOFER-ROOB ET AL
correlated inversely with (r ~  ""0.48, P  <  0,0001), as 
expected* because of disease progression with age. Because of 
continuous nutritioiiai support, the majority of patients had 
good nutritional status: median Z scores for upper arm circum­
ference for the Swiss group were —1.26 ( — 3,94-2.88) and for 
body weight were —0.80 ( —3.13-3,73), compared with Swiss 
reference values established by Prader et al (28). There were no 
major differences in the overall therapeutic regimen for CF 
patients among the participating CF centers, nor did patients 
differ with respect to age and disease seventy (Table 1). About 
one-third (21 of 62) of the Swiss group had taken ß-carotene 
supplements (0,5 mg fl/Z-fw/M’-ß-carotene ■ k g ~ ! • c T 1) long­
term before this investigation in addition to vitamin E. These 
patients were enrolled only in the overall comparison of vita­
min C status between Swiss and Austrian patients, not in the 
study of correlations between vitamin C status and indexes of 
inflammation because ß-carotene status has been shown to 
affect at least one of the indexes of inflammation assessed in 
this study (29).
Subgroups of the patients included in this observational 
study had been enrolled previously in either a vitamin E (36 
patients from group A, ie, 32 Swiss and 4 German patients, and
13 patients from group B, ie, Austrian patients, further referred 
to as the Swiss/Austrian group) or ß-carotene (54 patients from 
group B, ie, Austrian patients only, further referred to as the 
Austrian group) supplementation trial, with 7 Austrian patients 
enrolled in both. These studies were conducted 2 y apart, 
allowing for investigation of vitamin C status in the same 
season (summer) and for all patients enrolled in the ß-carotene 
trial to be in a steady state for vitamin E status. Forty-seven 
patients enrolled in the vitamin E supplementation study had a 
second determination of plasma vitamin C concentrations after 
they had taken 268 mg RRR-a-tocopherol (400 !U)/d for 2 mo, 
and 28 patients enrolled in the ß-carotene supplementation trial 
after they had taken 0.5 mg all-trans-ß-c  aróte ne * kg' 1 * d ~ 1 
for 12 mo. Possible seasonal changes were evaluated every 3 
mo in 26 patients receiving vitamin E supplements long-term 
and followed up for 12 mo in the absence of changes in the 
therapeutic regimen (placebo group o f  the ß-carotene supple­
mentation trial). Details of the vitamin E study were reported 
(30) and a report is in preparation for the ß-carotene supple­
mentation trial.
Patients were compared with 34 healthy Swiss adults, me­
dian age 25.7 y (19.0-43.8 y), who volunteered as control 
subjects; it was not considered ethically acceptable to enroll 
healthy children. Patients received either no or 30-150 mg 
(median 40 mg) vitamin C from multivitamin supplements 
daily (different preparations i rom  different companies); these 
doses were not changed during the observation periods. Con­
trol subjects consumed an average diet and did not take sup-
;s. All investigations were approved by the Ethics Com­
mittees of either the Department of Pediatrics, University of 
Zurich, Switzerland, or the Faculty o f  Medicine, University of 
Innsbruck, Austria, and informed consent was obtained from 
the patients or their parents and from the control subjects.
Analytic m ethods
Blood was drawn after an overnight fast into tubes contain­
ing either potassium EDTA or lithium heparin, protected from 
light with aluminum foil where indicated, and centrifuged 
immediately at 2000 X g for 8 min at room temperature;
plasma was separated and the different aliquots were processed 
as follows. For plasma total vitamin C determinations, 0.5 niL 
plasma with heparin was mixed with 4.5 mL 5% (wt:vol) 
metaphosphoric acid within a maximum of 30 min after blood 
was drawn and kept at - 8 0  °C until analyzed in the laboratory 
of the Vitamin Research Department of Hoffmann-La Roche 
(Basel, Switzerland); a fluorimetrie method with iodine oxida­
tion followed by condensation with 1,2-phenylenediamine was 
used (31). Plasma samples with EDTA for MDA determination 
were also stored at — 80°C until analyzed; the HPLC MDA- 
thiobarbituric acid method used was based on the method of 
Wong et al (32) as described previously, with a mean (±  SD) 
of 0.61 ±  0.22 jimiol/L used as the reference value for healthy 
subjects (33). Aliquots for the determination of the fat-soluble 
antioxidants «-tocopherol and ß-carotene were stored at 
- 2 0  °C for a maximum of 4 d before analysis; the HPLC 
method of Hess et al (34) was used. The other samples were 
either processed immediately or stored at - 8 0  °C until ana­
lyzed. Plasma concentrations of N E /« ,-PI complexes were 
determined by enzyme-linked immunosorbent assay (ELISA) 
with a test kit from Merck (Darmstadt, Germany), as published 
recently (29), with 45,6 ±  18.7 /xg/L used as the reference 
value for healthy subjects. TNF-« (normal <  20 ¡xg/L) and 
IL-6 concentrations (normal <  3 ng/L) were determined by 
ELISA with test kits from Medgenix Diagnostics (Fleurus, 
Belgium), and « r AGP by nephelometry using the QM300 
A AG antibody from Sanofi Diagnostics Pasteur (Chaska, MN) 
(normal <  1.2 g/L). The normal percentage of white blood 
cells classified as bands in our laboratory was < 1 5 % .
Statistical analyses
To obtain approximately normal distributions, some vari­
ables had to be either log-transformed or square root-trans­
formed. In all cases the transformation that resulted in the best 
approximation of a Gaussian distribution was applied, Pearson 
correlations and multiple-regression analysis were used to 
study relations between plasma ascorbic acid concentrations 
and different variables. To correct for the influence of age, 
partial correlations were calculated, Repeated-measures analy­
sis of variance (ANOVA) was applied to analyze seasonal 
changes in different variables. STATGRAPHICS Plus for W in­
dows, version 1 (STSC, Rockville, MD) and GRAPHPAD 
INSTAT, version 2 (GraphPad Software, San Diego) were used 
for statistical procedures. P <  0.05 was considered significant. 
Values are expressed as means ± SDs unless otherwise 
indicated.
RESULTS
CF patients compared with healthy subjects
Plasma total vitamin C concentrations in the whole patient 
group did not differ significantly from those in healthy control 
subjects (Table 1). Plasma ß-carotene concentrations (log- 
transformed) were significantly lower in patients than in the 
control subjects (P <  0.0001), whereas «-tocopherol and MDA 
concentrations (both log-transformed) did not differ. Plasma 
vitamin C concentrations in the Swiss and Austrian groups 
were similar. Plasma a-tocopherol and ß-carotene concentra­
tions were higher in the Swiss group (P <  0.0001) but there 
were no differences for MDA concentrations.
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Plasma vitamin C concentrations and age, Shwaehman  
score, and overall nutritional status
Multiple-regression analysis, including plasma vitamin C con­
centration as the dependent variable and age (square root-trans­
formed) and Shwaehman score (VTliX) — Shwaehman score]) as 
the independent variables, showed lower vitamin C concent rations 
in older patients (P -  0.001) (Figure 1), but no dependency on 
Shwaehman scores (data not shown), No relations between 
plasma vitamin C concentrations and sex and population (Austrian 
or Swiss) were found, In the Swiss group (n =  62), data on upper 
arm circumference (Z scores), considered a reliable index of 
nutritional status in CF, were available and showed a positive 
correlation with vitamin C concentrations 0 ’ — 0.32, P =  0.04).
Correlations between plasma Yitamin C concentrations 
and indexes of lung inflammation
Because different indexes were investigated in the two pa­
tient groups, further correlations were studied only in either 
one of the two groups. Data from the Swiss/ Aus trian group 
enrolled in a vitamin E supplementation trial were used from 
the second examination after patients had received 400 IU 
ÆÆÆ-a-toeopheroJ/d for 2 mo, and the Austrian group had their 
vitamin E status corrected long-term before entry into the 
ß-carotene supplementation trial; thus, both groups had normal 
vitamin E status because of efficient vitamin E supplementa­
tion. Both the second investigation of the Swiss/Austrian group 
and the first of the Austrian group were conducted in .summer. 
In the Swiss/Austrian group, three indexes of inflammation 
showed significant inverse correlations with plasma vitamin C 
concentrations; bands as a percentage of WBC count
(/* = "0 .36, P = 0.02), tv,-AGP (/• =  -0 ,4 5 ,  P = 0.002), and
N E/«,-PI complex concentrations (r =  —0,34, P “  0.02) 
(Figure 2). in the Austrian group, W BC count (/■ — -“0.36, 
P = 0,008) and plasma 1L-6 concentrations (r “  -0 .4 6 ,  P “  
0.0006) correlated inversely with plasma vitamin C concentra­
tions (Figure 3), whereas T N F-a  did not (data not shown). 
Because plasma vitamin C concentrations showed age-de pen­
dency, as did disease severity, partial correlations of vitamin C 
with these indexes were calculated, with the influence of age 
controlled for (Table 2). The influence of age was more 
pronounced in the Swiss/Austrian group (on bands, « r AGP,
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and N E /« r Pl complex concentrations) compared with the 
Austrian group (on WBC count and 1L-6 concentrations).
Changes in plasma vitamin C concentrations during 
vitamin E and ß-carotene supplementation
During supplementation with 400 IU /Mtf-<v-locopherol/d 
for 2 mo (starling in spring) plasma vitamin C concentrations 
increased slightly but not significantly (Table 3). There were 
no changes in vitamin C concentrations in patients taking 0,5 
mg i///-//Y///.v-ß-carotene • kg 1 • d 1 for 12 mo.
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FIGURE 3. Inverse correlations between plasma vitamin C concentra­
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Seasonal changes in p lasm a vitam in C concentrations
In 23 of the 26 Austrian patients who took vitamin E sup­
plements long-term and were followed up for 12 mo without 
changes in vitamin E supplementation and other aspects of the 
therapeutic regimen, and who also had a complete set of data 
for the different variables, plasma vitamin C concentrations 
increased from the first investigation in August to the second in 
November, achieved a plateau up to February and then dropped 
between February and May (P <  0.01 ) without further changes 
between May and August (F igure 4). Values at the beginning 
and end of the 12-mo study period (both in August) did not 
differ from each other, Plasma vitamin C concentrations were 
significantly higher in February than in August and May 
{P <  0,01). Looking at the changes in the individual patients in 
vitamin C status only, plasma vitamin C concentrations were 
highest in February in 11 of 26 patients and lowest in August 
and May in 16 of 26 and 8 of 26, respectively. Because two 
investigations were conducted in August, the frequencies of 
lowest values in August (16 of 26) and May (8 of 26) can be 
considered equal Thus, on an individual basis, plasma vitamin 
C concentrations were also highest in winter and lowest in 
spring and summer, The mean CV in plasma vitamin C con­
centrations over a whole year, calculated for the 26 individual 
subjects, was 14,3% (1 .4 -4 2 ,1 %)«
Concom itant changes in lipid peroxidation and T N F-a 
concentrations
The significant increase in plasma vitamin C concentrations 
from August to February in 23 patients was accompanied by a 
small decreavse in plasma MDA concentrations; the significant 
drop in plasma vitamin C concentrations between February and 
May was accompanied by a significant increase in MDA con­
centrations (P <  0.001, repeated-me a su res ANOVA; Figure 4), 
Both plasma vitamin C and MDA concentrations returned to 
baseline values after 12 mo. TNF-tv concentrations were sig­
nificantly elevated in May compared with August and February 
(P <  0.01), decreased thereafter, and values at the end of the 
study period were comparable with those at the beginning 
(Figure 4), Thus, plasma vitamin C, MDA, and TNF-a con­
centrations showed a distinct pattern that was inverse for MDA 
and TNF-o! compared with vitamin C concentrations. No cor­
responding changes in WBC counts and IL-6 concentrations 
were observed (data not shown).
DISCUSSION
The data presented show that plasma total vitamin C con­
centrations in CF patients are widely scattered and scorbutic 
concentrations, ie, <  11 jamoI/L (35) can be observed occa­
sionally. The average values, however, are only slightly lower 
in CF patients than in healthy adult subjects when the majority 
of patients are taking low-dose vitamin C supplements and the 
control subjects are not taking supplements. Even though age- 
matched healthy control subjects (aged 0-38 y) would have 
been preferable, comparison with the control subjects of this 
study (aged 19-44 y) seemed to be appropriate because plasma 
vitamin C concentrations in a French population showed no 
evidence of a distinct evolutionary pattern of plasma vitamin C 
concentrations between the ages of 6 and 40 y (36).
There were no differences between patients from Switzer­
land and Austria, in contrast with elevated plasma ascorbic acid 
concentrations in CF patients from England that were associ­
ated with impaired total radical-scavenging potential (23), 
There were no signs of increased lipid peroxidation in the 
patients o f  our study, most likely because of efficient vitamin 
E supplementation. Whereas a small but nonsignificant in­
crease in plasma vitamin C concentrations was observed during 
2 mo of vitamin E supplementation, no changes occurred 
during 12 mo of ß-carotene supplementation, suggesting that 
no major interactions between these antioxidants and vitamin C 
take place,
Given the progressive nature of CF lung disease, a relation 
between age and disease severity, assessed by Shwaehman 
scores, was expected for individual patients, but it also held 
true for the study patients as a group. In line with this obser­
vation, different indexes of inflammation also correlated pos­
itively with age. In general, this can be explained by more 
advanced lung disease in the older patients because healthy 
subjects o f  a similar age range do not show an increase with 
age, for instance, in a r AGP (37, 38), the variable that showed 
the closest correlation with age in CF patients. However, that 
older patients would have lower plasma vitamin C concentra­
tions than younger ones could not be expected a priori, but is 
in line with an observation made in another group of C F  
patients (24). When age and Shwaehman scores were entered
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TAULE 2
Pearson and partial correlations Tor plasma vitamin C concentrations and indexes of inflammation in two cohorts of cystic fibrosis patients taking 
vitamin E but not jtf-earotene'
Vitamin C concentration
Pearson correlation
■prt”
Partial correlation
r P r P
Swiss/Austrian group (n = 47 )2 
Bands (% of white blood cells) -0 .36 0.02 — 0.19 0.20
tv r  Ac id glycoprotein -0 .45 0.002 -0 .29 0.05
Neutrophil elastase/rt j-proteinase inhibitor (U>g10) -0 .3 4 0.02 ■a 17 0.25
Austrian group (// “  5 1)-* 
Interleukin 6 (logH)) -0 .4 6 0,0006 "■“0.44 0.001
White blood cell count ( l o g ^ -0 ,36 0.008 ..0,39 0.004
1 Partial correlations were applied to control for age.
" A lier 2 mo of 268 mg (400 IU) AWi-cv-tocopherol/d. Includes four patients from Germany. 
•'After long-term vitamin E supplementation ( 100—400 lU/d).
 ^fi “  50.
into multiple-regression analysis, only age was an explanatory 
variable for plasma vitamin C concentrations and Shwaehman 
scores were not. This seems surprising, but can be explained by 
the fact that in contrast with current vitamin C status, Shwach- 
man scores are highly influenced by the long-term disease 
course, including irreversible lung damage that may have oc­
curred years ago. Data on the long-term evolution of plasma 
vitamin C concentrations and Shwaehman scores are needed to 
establish a possible cause and effect relation between lower 
plasma vitamin C concentrations and lower Shwaehman scores 
in older patients. The same holds true for the correlation 
between vitamin C status and lung function, both of which 
have been shown recently to correlate negatively with age in 
CF patients (24). Therefore, the question of whether impaired 
vitamin C status facilitates the progression o f  lung disease in 
CF patients long-term, or whether patients with more advanced 
lung disease have lower plasma vitamin C concentrations as a
TAKLR3
Changes in plasma concentrations oí vitamin C, or-toeophemh and ß- 
carotene in cystic fibrosis patients du ring vitamin B and ß-carotene 
supplementation7
r t i- lh  ‘f f  n------------■ 11 ^ ¥ r t i  |  i r t i  h i  if rrrrr
ViLamin C «-Tocopherol ß-Carotene
MM»««
fit un I/L
Vitamin H supplementation 
of Swiss/Austrian group 
(/i c.‘r¡ 47)*•
Baseline
2 mo
ß-Carotene supp lenient« lion 
of Austrian group 
(// ~ 28.)^
Baseline
12 mo
61.2 ± 19.7 
66.1 ± 20,4
17.3 12.0 0.14 0.25 
31.0 *. 9.1X* 0.15 0.29
64.7 ± 17.3 21.6 ± 7.38 
63.3 ±  15.9 20.8 £  6.65
0.11 ¿0.16 
0.99 Z 0.64*
/ j  4 .
■w
2 268 mg {400 IU) AVM-iMocopherol/d. Group includes four patients
from Germany.
■* Significantly different from baseline, P <  0.0001 (Wilcoxon mulched-
pairs signed-rank test).
#/0.5 mg/kg water-miscible ¿///-m/m-ß-earoteneAL
result of lower vitamin C intake or increased vitamin C de­
mands or both when they are sicker, remains open.
In critically ill patients (19) and smokers (22), low plasma 
and leukocyte vitamin C concentrations cannot be explained 
entirely by low intake of vitamin C, which raises the question 
of increased ascorbic acid turnover or consumption. We did not 
estimate the vitamin C intake in this study, because the vitamin 
C content of a specific food item varies considerably, depend­
ing on its source (39), storage time, and food preparation, all of 
which can hardly be accounted for in the evaluation of dietary 
records of patients consuming a free diet and not admitted to 
the hospital. Patients took either no or a dose of median 40 mg 
vitamin C daily in multivitamin supplements. Possible effects 
on plasma vitamin C concentrations of these low doses may 
have been easily hidden by differences in dietary intakes of 
vitamin C. Therefore, relations between supplement intake and 
plasma concentrations were not analyzed,
Seasonal variations in plasma vitamin C concentrations were 
observed, with similar values at the beginning and the end of 
the 12-mo study period in August. Values were highest in 
winter and lowest in summer. Plasma «-tocopherol and ß-car­
otene concentrations did not change. Interestingly, plasma 
M DA concentrations showed inverse behavior, with the high­
est values in May when plasma vitamin C concentrations were 
lowest; they also returned to baseline values at the end of the 
12-mo study period. TNF-cv concentrations were also highest in 
May and returned to baseline values. These simultaneous sea­
sonal changes suggest a dependency of one or more indexes on 
the others, but certainly are not .sufficient to prove lhaL one 
exists. A possible explanation is that in spring vitamin C status 
was not sufficient to efficiently neutralize oxidant stress, re­
sulting in increased lipid peroxidation. The simultaneous in­
crease in TNF-cv concentrations may reflect increased produc­
tion of this cytokine by alveolar macrophages, either as a cause 
or consequence of increased ROS release in the presence of 
lower vitamin C concentrations. Although a 1-y follow-up 
study of healthy subjects did not note changes in plasma 
ascorbic acid concentrations (40), another study in the elderly 
showed the highest plasma total vitamin C concentrations and 
lowest C-reactive protein concentrations in summer, in associ-
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FIGURE 4, Boxplols for plasma vitamin C, malondialdehyde (MDA), 
and lu mor necrosis factor a (TNF-cy) concentrations arc shown for five 
time points with 3-mo intervals in 23 patients (starling in August) taking 
vitamin K blit not /J-carolale (placebo group of the ß-carotene trial). See 
Methods for details of the studies. Significant differences with repented- 
111 ensures ANOVA with Tu key-Kramer multiple comparisons test: for 
vitamin C in February compared with August {beginning and end) and 
May, P <  0.01; for MOA tlogH)) in May compared with August (begin­
ning)* P < 0 .01, and May compared with November, February, and August 
(end)» P < 0.001; for TNF-« (log1u) in May compared with August 
(beginning), P <  0.001, and May compared with February and August 
(end) P < 0.01). Nolo that mean plasma MDA concentrations of healthy 
subjects are 0.72 /xmol/L (log,,, -  -0.14) and normal TNF-or eoncenlra- 
(ions are < 20 /xg/L (log,,, -  1.30). The boxplots divide the dala into four 
areas of equal frequency: the box encloses the middle 50% of dala; the 
median is the horizon lai line and the mean value the the lower (upper) 
whisker is drawn from the lower (upper) quartilc to Ihe smallest (largest) 
dala poini within 1.5 interquartile ranges from the lower (upper) quaitile; 
individuili poi nls are dala points that fall vv till in three interquartile ranges 
(suspect outliers); no far outliers were observed.
atitiii with 'higher vitamin C intake in summer (41), Lower 
vitamin C intake, either from food or supplements, or both, 
could he a plausible explanation for the decrease in plasma 
vitamin C concentrations in our study as well, but in the
absence of intake data, redistribution of vitamin C from plasma 
to the site of inflammation should be considered as well,
For further study, confounding seasonal influences were 
excluded by analyzing data obtained in the same season, ie, 
from the second examination of the Swiss/Austrian group and 
the first of the Austrian patients, both of which were conducted 
in summer. Low plasma vitamin C concentrations were asso­
ciated with increased proinflammatory cytokine release 
(TNF-a and IL-6), enhanced hepatic acute phase response 
(ttpAGP), increased plasma NE/cY|-PI complex concentra­
tions, and elevated WBC and band counts. The association with 
IL-6 concentrations and WBC count was significant even after 
the age influence (which, to an unknown extent, is proposed to 
reflect long-term disease progression) was controlled for. 
These findings are in line with observations in critically ill 
patients with different underlying diseases showing low plasma 
vitamin C concentrations associated with the severity of the 
illness and C-reactive protein concentrations (19), in elderly 
subjects with higher plasma vitamin C concentrations in asso­
ciation with lower C-reaetive protein concentrations (41), and 
in smokers, in whom 21% lower plasma ascorbic acid concen­
trations were associated with 38% higher TNF-« and 16% 
higher IL-6 concentrations than in nonsmokers (22),
Perhaps even more than smoking, bacterial infection stimu­
lates proin Ham ma tory cytokine production and the acute phase 
response and activates neutrophils to release ROS (3). Unop­
posed oxidants not only cause lipid peroxidation (eg, MDA 
formation), but enhance the production, for instance, of TNF-« 
and IL-6 (3, 4). ROS are likely to oxidatively inactivate the 
a r PI in the lung of CF patients (1, 17, 29). This may result in 
further neutrophil activation and proteolytic lung damage (2) 
and thus in propagation of the disease process. Under the type 
of oxidant stress that is exerted by activated neutrophils in CF 
(42), ascorbic acid is highly effective in vitro,
When human plasma was challenged with ROS released 
from activated neutrophils, ascorbic acid was depleted rapidly 
together with other antioxidants (43). Lipid peroxidation was 
prevented completely as long as ascorbic acid was present (43), 
perhaps because it intercepts oxidants in the aqueous phase 
before they can attack and cause detectable damage to lipids. In 
vitro experiments have shown that ascorbic acid protects a,-PI 
against inactivation during exposure to stimulated neutrophils 
(17). Taken together, these data suggest that ascorbic acid may 
indeed play an important role in protecting lung tissue from 
oxidant injury. Thereby, we speculate that ascorbic acid may 
accumulate at the site of inflammation* with enhanced uptake 
by activated inflammatory cells, and, as a consequence, plasma 
concentrations may decrease.
In ex vivo studies the low-density lipoprotein (LDL) of 
patients of this study, when efficiently supplemented with 
vitamin E, showed normal resistance to a defined oxidative 
stress (30). In vitro experiments identified 40 /xmol/L as the 
minimum concentration of ascorbic acid that significantly in­
hibited oxidative modification of LDL (11), Indeed, the ma­
jority of CF patients whose LDL was tested showed plasma 
vitamin C concentrations 40 /xmol/L. Interestingly, in pa­
tients with plasma vitamin C concentrations <  40 /xmol/L, i 
indexes of inflammation included in the current investigation 
were markedly increased, whereas those with concentrations 
>  80 jumol/L showed clearly lower values. These results sug­
gest that plasma vitamin C concentrations in the upper quart ile
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of our healthy control subjects (82.9—112.4 /miol/L) may ben­
efit CF patients. From correlation studies (44,45) we attempted 
to extrapolate the vitamin C dose that may be required for CF 
patients to reach the goal of steady state plasma concentrations
>  80 /xmol/L. One study showed that intake of >  200 nig 
vitamin C/d is associated with these target plasma concentra­
tions in «50%  of healthy individuals (44). Results from an­
other study suggest that daily doses as high as 1 g may be 
required, ie, the dose that led to complete plasma saturation in 
healthy subjects (45). By contrast, saturation of neutrophils 
occurred at 100 mg/d, again, in healthy subjects (45). Vitamin 
C pharmacokinetics and requirements may differ substantially 
between healthy subjects and CF patients. Clearly, further 
studies are needed to establish both optimal plasma vitamin C 
concentrations and vitamin C intake in CF patients.
Even though correlations do not prove a cause and effect 
relation, the correlations between plasma vitamin C concent râ­
lions and different indexes of inflammation observed in CF 
patients in this study may be the first indications that vitamin 
C plays a role in the inflammatory disease process. In CF 
patients, interactions between nutritional status and infection 
and inflammation have been postulated, even though this is 
supported by indirect evidence such as higher life expectancy 
in patients receiving more aggressive nutritional support (46), 
rather than by clearly focused clinical trials. It remains to be 
shown in controlled intervention studies that improvement o f 
vitamin C status ameliorates inflammation in CF patients, not 
only short-term, but more importantly, long-term. Although 
intake of up to 1 g vitamin C/d appears to be safe in healthy 
subjects (45, 47), vitamin C may act as a prooxidant under 
certain conditions (48). These include pathologie events in 
which iron is unloaded from its main carrier proteins, trans­
ferri n and lactofcrrin. This may, in general, be the case in the 
low-pH microenvironment o f  activated phagocytes (49) and, 
specifically, in the Pseudomonas ueruginosu-Anhciüá lung of 
CF patients (50). Therefore, before supplementation with higb- 
dose vitamin C in CF patients can he recommended, controlled 
clinical studies addressing the issue of potential adverse effects 
need to be conducted. H
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